Skip to main navigation
Skip to search
Skip to main content
Arizona Board of Regents Home
Search content at Arizona Board of Regents
Home
Profiles
Departments and Centers
Scholarly Works
Grants
Activities
Equipment
Datasets
Press/Media
Prizes
Nephrotoxicity of epigenetic inhibitors used for the treatment of cancer
N. E. Scholpa
, R. T. Kolli
, M. Moore
, R. D. Arnold
, T. C. Glenn
, B. S. Cummings
Pharmacology and Toxicology
Research output
:
Contribution to journal
›
Article
›
peer-review
8
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Nephrotoxicity of epigenetic inhibitors used for the treatment of cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Cancer Treatment
100%
Nephrotoxicity
100%
Trichostatin A
100%
Cancer Cell
60%
Chemotherapy
40%
Prostate Cancer
40%
Histone Deacetylase Inhibitor
40%
Docetaxel
40%
Carbamazepine
40%
Methylation
20%
Multiple Myeloma
20%
Combination Therapy
20%
Cytotoxicity
20%
Cell Growth
20%
Antineoplastic Activity
20%
Cisplatin
20%
Cell Line
20%
Cell Viability
20%
Anticonvulsant
20%
Cell Damage
20%
Proteinase Inhibitor
20%
Kidney Cell
20%
P21
20%
Histone Deacetylase
20%
Decitabine
20%
DNA Methyltransferase
20%
Carfilzomib
20%
Acetylation
20%
CDK Inhibitor
20%
DNA Methyltransferase Inhibitor
20%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Nephrotoxicity
100%
Trichostatin A
100%
Prostate Cancer
40%
Histone Deacetylase Inhibitor
40%
Carbamazepine
40%
Docetaxel
40%
Combination Therapy
20%
Injury
20%
Multiple Myeloma
20%
Cytotoxicity
20%
Cell Viability
20%
Histone Deacetylase
20%
Anticonvulsive Agent
20%
Proteinase Inhibitor
20%
Cisplatin
20%
DNA Methyltransferase
20%
Decitabine
20%
Carfilzomib
20%
DNA Methyltransferase Inhibitor
20%
Keyphrases
MTT Staining
66%